New cancer drug trial halted early – what we know

NCT ID NCT05198349

Terminated Disease control Sponsor: EMD Serono Research & Development Institute, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested an experimental oral drug called M1069 in 15 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminated early, so results are limited and it is unclear if the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: M1069 (oral drug)
What this could lead to: If successful, M1069 could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This was a very early (Phase 1) trial with only 15 participants, and it was terminated early, so we have limited data on safety and effectiveness. The drug may cause serious side effects and may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC OR LOCALLY ADVANCED UNRESECTABLE SOLID TUMORS

Contacts and locations

Locations

Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Princess Margaret Cancer Centre

Toronto, Canada
Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium)

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.